Glenmark gets DCGI notice over 'false claims', price of Covid drug FabiFlu

The 'subject' of the letter was stated as: "Regarding the false claims and pricing of tab FabiFlu 200 mg (favipiravir) by Glenmark Pharmaceuticals Limited, India"

India's drug regulator has sought a clarification from Glenmark Pharmaceuticals over its alleged "false claims" about the use of anti-viral FabiFlu on Covid-19 patients with comorbidities and also over the "pricing" of the drug, after receiving a complaint from a member of Parliament.

In a letter to the Mumbai-based company, Drugs Controller General of India (DCGI) Dr. V G Somani stated that his office received a representation from an MP that the total cost of the treatment with FabiFlu (favipiravir) will be around Rs 12,500 and that the"cost proposed by Glenmark is definitely not in the interest of the poor,